Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.23
-0.16 (-0.68%)
At close: Mar 13, 2026, 4:00 PM EDT
23.71
+0.48 (2.07%)
After-hours: Mar 13, 2026, 7:45 PM EDT
Catalyst Pharmaceuticals Revenue
In the year 2025, Catalyst Pharmaceuticals had annual revenue of $588.99M with 19.78% growth. Catalyst Pharmaceuticals had revenue of $152.61M in the quarter ending December 31, 2025, with 7.61% growth.
Revenue (ttm)
$588.99M
Revenue Growth
+19.78%
P/S Ratio
4.82
Revenue / Employee
$3,236,203
Employees
182
Market Cap
2.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 588.99M | 97.26M | 19.78% |
| Dec 31, 2024 | 491.73M | 93.53M | 23.49% |
| Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
| Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
| Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
| Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
| Dec 31, 2019 | 102.31M | 101.81M | 20,361.20% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 488.96K | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Tarsus Pharmaceuticals | 451.36M |
| Arcutis Biotherapeutics | 376.07M |
| Arcus Biosciences | 247.00M |
| IDEAYA Biosciences | 218.71M |
| Beam Therapeutics | 139.74M |
| Viridian Therapeutics | 70.85M |
CPRX News
- 5 days ago - Catalyst Pharmaceuticals, Inc. (CPRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - GlobeNewsWire
- 17 days ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - GlobeNewsWire
- 19 days ago - Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - GlobeNewsWire
- 24 days ago - Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs - Seeking Alpha
- 4 weeks ago - Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals, Inc. (CPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha